AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$ALKS

Hopkinson Craig C. sold $423K of ALKS

Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares of Alkermes plc. (ALKS) at $46.99 ($0.42M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hopkinson Craig C.
Published Sep 1, 2026, 11:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 11:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALKS
Neutral
medium confidence
Mentioned
$ALKS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The transaction is a routine 10b5‑1 sale; unlikely to alter market perception.

02

Market read

Minor relevance; provides transparency but no actionable trading signal.

03

What to watch

No indication of upcoming clinical data or regulatory events that could affect price.

Relevance 3/10Novelty 4/10Timing: same day filing

Background

Alkermes plc. is a UK‑listed biotech focused on CNS disorders. Insider sales are disclosed via Form 4.

Company-level read

Ticker impact

$ALKSNeutralMedium confidence
Context

SEC Form 4 shows EVP R&D sold 9,000 shares for $422,874 on 2026-09-01.

Expected impact

Minor downward pressure; unlikely to move price materially.

Evidence & confidence

Sale represents ~6.5% of insider's remaining position; typical for 10b5‑1 plans.

Market effects

Sector

Limited impact on biotech sector; insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; may be purely liquidity driven.

Key entities

  • Officer
    Craig C. Hopkinson

    EVP R&D, Chief Medical Officer at Alkermes

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALKS insider trading history →

Related articles

SEP 26
$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

insidermonkey.com2 min
SEP 24
$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

investing.com2 min
SEP 22
$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

medscape.com3 min
SEP 21
$ALKSMedAI 8/10

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.

benzinga.com2 min